<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741234</url>
  </required_header>
  <id_info>
    <org_study_id>SB939-2006-001</org_study_id>
    <nct_id>NCT00741234</nct_id>
  </id_info>
  <brief_title>A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine</brief_title>
  <official_title>A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S*BIO</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>S*BIO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will
      assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with
      advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in
      cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and
      tolerability of SB939 in combination with standard azacitidine therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of SB939, administered orally every other day 3 times a week for 3 consecutive weeks, repeated every 4 weeks, either alone (Arms A and B), or in combination with azacitidine therapy in (Arm C).</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish the maximum tolerated dose and a recommended phase II dose of SB939 as a single agent when administered every other day 3 times a week for 3 consecutive weeks, repeated every 4 weeks</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the dose limiting toxicities of SB939</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic profile of SB939</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess histone acetylation in PBMC and other biomarkers</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To document anti-tumor activity</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Hematologic Malignancies</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced hematologic malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Myelodysplastic Syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB939</intervention_name>
    <description>SB939 taken orally in a 4-week cycle.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine taken orally with SB939 in a 4-week cycle</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Arms A &amp; B:

          -  Patients with solid tumors in Arm A and hematologic malignancies in Arm B that is
             classified as intermediate 1 or greater according to the International Prognostic
             Scoring System (IPSS) risk category for whom therapy is indicated;

          -  ECOG performance status (PS) 0-2;

          -  Patients must have adequate non-hematologic organ system function.

        Arm C:

          -  Patients with MDS that is classified as intermediate 1 or greater according to the
             International Prognostic Scoring System (IPSS) risk category for whom therapy is
             indicated;

          -  Have not been treated with azacitidine and are a candidate for treatment with
             azacitidine;

          -  ECOG performance status (PS) 0-2;

          -  Patients must have adequate non-hematologic organ system function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Wilding, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boon Cher Goh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Han Chong Toh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Chuah, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Garcia-Manero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Singapore</city>
        <zip>160610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SB939</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Combination with azacitidine</keyword>
  <keyword>Solid malignancies</keyword>
  <keyword>Hematologic malignancies</keyword>
  <keyword>HDAC inhibitor</keyword>
  <keyword>Refractory to standard therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

